Rhythm Pharmaceuticals, Inc. (RYTM)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$105.02-5.11%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · RYTM
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -11.9% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| 84.1% |
Growth built into the price is above our model estimate.
The price assumes 96.0 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-05 · Compared with 116 industry peers · Company calendar date is not available
RYTM — director transition
Dated 2026-04-03
Director — Edward T. Mathers: Mr. Mathers resigned from the Board without any disagreement.
Why it matters: Rhythm is still loss-making, while costs rose in the first half. Spending above the updated range would add pressure to cash use.
Worry if2026 non-GAAP operating costs exceed $397 million for the full year.
Less concerning ifFull-year 2026 non-GAAP operating costs are $363 million to $397 million, or less.
Why it matters: RM-718 showed an 11.6% mean BMI drop at 16 weeks in seven patients. More data can test whether that early result holds.
Supportive ifA later RM-718 update shows a mean BMI drop near or above 11.6% at 16 weeks, with more than seven patients assessed.
Worry ifA later update shows a smaller mean BMI drop, or reports safety issues that limit treatment.
Why it matters: A trial start would move a second MC4R drug into late-stage testing for acquired HO. A missed year-end goal would slow that plan.
Supportive ifRhythm starts its key Phase 3 bivamelagon trial for acquired HO by December 31, 2026.
Worry ifNo pivotal Phase 3 trial has started by December 31, 2026, or Rhythm reports a delay.
Why it matters: Q2 revenue reached $71.3 million, up 19% from Q1. Further growth would show the new U.S. launch is adding to sales.
Supportive ifQ3 global IMCIVREE revenue is above $71.3 million, and reimbursed patients increase from Q2.
Worry ifQ3 global IMCIVREE revenue is $71.3 million or lower, or reimbursed patient growth stalls.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$133 on $10,000 · ±1.3% | How much price usually moves either way. |
| Bad day | $517 loss on $10,000 · 5.2% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,554 loss on $10,000 · 35.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.